Vistagen Therapeutics

(NASDAQ) VTGN

Current Price$0.72

Market Cap$25.30M

Since IPO (2011)-100%

5 Year-99%

1 Year-66%

1 Month+12%

Vistagen Therapeutics Financials at a Glance

Market Cap

$25.30M

Revenue (TTM)

$1.27M

Net Income (TTM)

-$69.69M

EPS (TTM)

-$1.87

P/E Ratio

-0.33

Dividend

$0.00

Beta (Volatility)

2.21 (High)

Dividend

$0.00

Beta (Volatility)

2.21 (High)

Price

$0.72

Volume

27,343

Open

$0.65

Price

$0.72

Volume

27,343

Open

$0.65

Previous Close

$0.72

Daily Range

$0.65 - $0.73

52-Week Range

$0.43 - $5.14

Estimated Earnings Date

Aug 6, 2026

Dividend

$0.00

Beta (Volatility)

2.21 (High)

Price

$0.72

Volume

27,343

Open

$0.65

Previous Close

$0.72

Daily Range

$0.65 - $0.73

52-Week Range

$0.43 - $5.14

Estimated Earnings Date

Aug 6, 2026

VTGN News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Vistagen Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Shawn K. Singh

Website

www.vistagen.com

Headquarters

South San Francisco, CA 94080, US

VTGN Financials

Key Financial Metrics (TTM)

Gross Margin

71.81%

Operating Margin

-5678.74%

Net Income Margin

-5487.01%

Return on Equity

-133.02%

Return on Capital

-197.26%

Return on Assets

-143.49%

Earnings Yield

-3.03%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$25.30M

Shares Outstanding

41.03M

Volume

27.34K

Avg. Volume

910.95K

Financials (TTM)

Gross Profit

$912.00K

Operating Income

-$72.12M

EBITDA

-$69.40M

Operating Cash Flow

-$66.44M

Capital Expenditure

-$190.00K

Free Cash Flow

-$66.50M

Cash & ST Invst.

$45.40M

Total Debt

$1.04M

Vistagen Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2026YOY CHG

Revenue

$465.00K

+3200.0%

Gross Profit

$465.00K

+3200.0%

Gross Margin

100.00%

N/A

Market Cap

$25.30M

N/A

Market Cap/Employee

$527.10K

N/A

Employees

N/A

Net Income

-$16.27M

-19.4%

EBITDA

-$16.53M

-22.7%

Quarterly Fundamentals

Name

Q4 2026YOY CHG

Total Cash

$45.40M

-43.6%

Total Debt

$1.04M

-30.8%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$249.00K

-73.7%

Short Term Debt

$795.00K

+41.7%

Return on Assets

-1.43%

N/A

Return on Invested Capital

-2.02%

N/A

Free Cash Flow

-$16.20M

-59.6%

Operating Cash Flow

-$16.20M

-61.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ACTUActuate Therapeutics Inc

ACTUActuate Therapeutics Inc$1.68-14.29%

INOInovio Pharmaceuticals, Inc.

INOInovio Pharmaceuticals, Inc.$1.10+1.85%

MCRBSeres Therapeutics, Inc.

MCRBSeres Therapeutics, Inc.$7.08+3.43%

CGTXCognition Therapeutics, Inc.

CGTXCognition Therapeutics, Inc.$1.12-0.88%

SEERSeer, Inc.

SEERSeer, Inc.$1.66-4.05%

AGENAgenus Inc.

AGENAgenus Inc.$3.03+5.21%

SPROSpero Therapeutics, Inc.

SPROSpero Therapeutics, Inc.$2.26+11.88%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

AAPLApple

AAPLApple$283.78+0.03%

AALAmerican Airlines Group

AALAmerican Airlines Group$17.87+0.02%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$153.23+0.00%

ONDSOndas

ONDSOndas$7.83+0.02%

KEELKeel Infrastructure

KEELKeel Infrastructure$6.03+0.03%

HLHecla Mining

HLHecla Mining$15.54+0.03%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.67+0.04%

Questions About VTGN

What is the current price of Vistagen Therapeutics?

Vistagen Therapeutics is trading at $0.72 per share.

What is the 52-week range for Vistagen Therapeutics?

Over the past 52 weeks, Vistagen Therapeutics has traded between $0.43 and $5.14.

How much debt does Vistagen Therapeutics have?

As of the most recent reporting period, Vistagen Therapeutics reported total debt of $1.04M.

How much cash does Vistagen Therapeutics have on hand?

Vistagen Therapeutics reported $30.79M in cash and cash equivalents in its most recent financial results.

What is Vistagen Therapeutics’s dividend yield?

Vistagen Therapeutics does not currently have a dividend yield.

Vistagen Therapeutics

Vistagen Therapeutics Financials at a Glance

VTGN News

Vistagen (VTGN) Q1 R&D Expense Jumps 54%

Why VistaGen Therapeutics Stock Jumped Today

Why VistaGen Therapeutics Stock Is Soaring Today

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Vistagen Therapeutics

VTGN Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Vistagen Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About VTGN

What is the current price of Vistagen Therapeutics?

What is the 52-week range for Vistagen Therapeutics?

How much debt does Vistagen Therapeutics have?

How much cash does Vistagen Therapeutics have on hand?

What is Vistagen Therapeutics’s dividend yield?

Premium Investing Services